Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences

Overview

Journal Degener Neurol Neuromuscul Dis

Publisher Dove Medical Press

Date 2024 Dec 26

PMID 39723344

Authors

Santosh B Shirol

Riyaz Ahmed Saboor

Thomas Muller

Affiliations

Soon will be listed here.

Abstract

Purpose: Multiple sclerosis (MS) is a neurological disorder affecting almost 2.8 million people globally, approximately 80-85% of whom have the relapsing-remitting form of the disease (RRMS). There are several autoinjectors available for the administration of injectable disease-modifying therapies for the treatment of MS. The objective of the current study was to gain an understanding of factors related to patients' and nurses' autoinjector preferences, and to evaluate two autoinjectors for glatiramer acetate (MyJECT™ and CSYNC™) against those preferences.

Patients And Methods: Patients with RRMS and nurses experienced in training patients with an autoinjector were recruited from 12 health centers in Germany. Surveys were administered to patients and nurses and their answers to 13 questions over five categories (participants' characteristics, important autoinjector attributes, autoinjector performance, satisfaction with the autoinjector devices and demographics) were scored, where appropriate, using a 5-point Likert scale.

Results: A total of 15 patients and 15 nurses were included in the study. Overall, the top four most important attributes, for both nurses and patients, were ease of handling, ability to use independently, ease of gripping the autoinjector and ease of self-injection. MyJECT™ received a mean score of at least 4.5 (out of 5) on more attributes than CSYNC™ and satisfaction with both autoinjectors was high.

Conclusion: Nurses and patients with RRMS were highly satisfied with both the MyJECT™ and CSYNC™ autoinjectors, with scores suggesting that MyJECT™ performs better on the attributes they identified as most important. All patients currently using the MyJECT™ were likely or highly likely to recommend it to another patient with RRMS.

References

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I . Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Prefer Adherence. 2017; 11:1325-1334. PMC: 5548304. DOI: 10.2147/PPA.S137741. View

Rekaya N, Vicik S, Hulesch B, McDonald L . Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits. Rheumatol Ther. 2020; 7(3):537-552. PMC: 7410887. DOI: 10.1007/s40744-020-00216-5. View

Amtmann D, Bamer A, Kim J, Chung H, Salem R . People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures. Disabil Health J. 2017; 11(1):99-107. DOI: 10.1016/j.dhjo.2017.04.008. View

Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N . Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015; 9:951-9. PMC: 4501165. DOI: 10.2147/PPA.S85917. View

Sadigh G, Lava N, Switchenko J, Duszak Jr R, Krupinski E, Meltzer C . Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence. Mult Scler. 2020; 27(3):453-464. DOI: 10.1177/1352458520913977. View

Lange J, Richard P, Bradley N . Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population. Med Devices (Auckl). 2015; 8:255-64. PMC: 4461121. DOI: 10.2147/MDER.S85938. View

Goodin D . The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122:231-66. DOI: 10.1016/B978-0-444-52001-2.00010-8. View

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie R . Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26(14):1816-1821. PMC: 7720355. DOI: 10.1177/1352458520970841. View

10.

Bayas A . Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013; 10(3):285-7. DOI: 10.1517/17425247.2013.763793. View

11.

Phillips J, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A . An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011; 11:126. PMC: 3213083. DOI: 10.1186/1471-2377-11-126. View

12.

Barone D, Singer B, Merkov L, Rametta M, Suarez G . Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors. Neurol Ther. 2016; 5(2):155-167. PMC: 5130914. DOI: 10.1007/s40120-016-0047-3. View

13.

Bittner B, Richter W, Schmidt J . Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs. 2018; 32(5):425-440. PMC: 6182494. DOI: 10.1007/s40259-018-0295-0. View

14.

Tischer B, Mehl A . Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018; 12:1413-1424. PMC: 6080662. DOI: 10.2147/PPA.S169339. View

15.

Doshi A, Chataway J . Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016; 16(Suppl 6):s53-s59. PMC: 6329568. DOI: 10.7861/clinmedicine.16-6-s53. View

16.

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor B . Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11):1022-4. PMC: 4162299. DOI: 10.1212/WNL.0000000000000768. View

17.

di Cantogno E, Russell S, Snow T . Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence. 2011; 5:173-80. PMC: 3090378. DOI: 10.2147/PPA.S14903. View

18.

Travers B, Tsang B, Barton J . Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis. Aust J Gen Pract. 2022; 51(4):199-206. DOI: 10.31128/AJGP-07-21-6103. View

19.

Costello K, Kennedy P, Scanzillo J . Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008; 10(9):225. PMC: 2580090. View

20.

Xie Y, Tian Z, Han F, Liang S, Gao Y, Wu D . Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(27):e20885. PMC: 7337585. DOI: 10.1097/MD.0000000000020885. View